Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Meridian Bioscience's share price for the quarter that ended in Sep. 2022 was $31.53. Meridian Bioscience's Shares Outstanding (EOP) for the quarter that ended in Sep. 2022 was 43.7 Mil. Therefore, Meridian Bioscience's market cap for the quarter that ended in Sep. 2022 was $1,379.3 Mil.
Meridian Bioscience's quarterly market cap
increased
from Mar. 2022 ($1,131.1 Mil) to Jun. 2022 ($1,329.9 Mil) and
increased
from Jun. 2022 ($1,329.9 Mil) to Sep. 2022 ($1,379.3 Mil).
Meridian Bioscience's annual market cap
increased
from Sep. 2020 ($731.3 Mil) to Sep. 2021 ($834.3 Mil) and
increased
from Sep. 2021 ($834.3 Mil) to Sep. 2022 ($1,379.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Meridian Bioscience's Enterprise Value for Today is $1,444.5 Mil.
Meridian Bioscience Market Cap Historical Data
The historical data trend for Meridian Bioscience's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Meridian Bioscience's Market Cap
For the Diagnostics & Research subindustry, Meridian Bioscience's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meridian Bioscience's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Meridian Bioscience's Market Cap distribution charts can be found below:
* The bar in red indicates where Meridian Bioscience's Market Cap falls into.
Meridian Bioscience Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Meridian Bioscience's Market Cap for the fiscal year that ended in Sep. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meridian Bioscience (NAS:VIVO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Meridian Bioscience Market Cap Related Terms
Thank you for viewing the detailed overview of Meridian Bioscience's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Meridian Bioscience (Meridian Bioscience) Business Description
Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIVO has been successfully added to your 